Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Onychomycosis: Epidemiology, Diagnosis, Topical Therapy
Description
The presentation discusses onychomycosis, the most prevalent nail disorder in clinical practice, underscoring its increasing prevalence following a recent New York Times article. Key risk factors include obesity, peripheral vascular disease, diabetes, HIV, and especially tinea pedis, which greatly increases the likelihood of onychomycosis. The majority of cases stem from dermatophytes, primarily Trichophyton rubrum, with the potential for misidentified non-dermatophyte yeasts necessitating confirmatory testing. Diagnostic techniques vary, with methods such as KOH microscopy, fungal culture, histology, and PCR offering different advantages and limitations. The clinical manifestation typically involves distal lateral subungual onychomycosis, characterized by specific symptoms like onycholysis and subungual hyperkeratosis. There is a discussion of various onychomycosis types, including the lesser-known dermatophytoma, which responds better to topical treatments. Treatment options remain limited, with three FDA-approved topicals: ciclopirox, efinaconazole, and tavaborole, each with distinct mechanisms and efficacy. New potential treatments are on the horizon, including a topical terbinafine solution and other compounds still in trials. The presentation emphasizes the importance of establishing a precise diagnosis before treatment, recognizing the dermoscopic features of the condition, and highlights ongoing developments in effective therapies.
View moreConclusions
- The primary risk factor for onychomycosis is tinea pedis, which significantly increases the likelihood of infection.
- Dermatophytes, particularly T. rubrum, are the main pathogens responsible for onychomycosis.
- Biofilms contribute to the pathogenicity of onychomycosis, complicating treatment efforts.
- Various clinical presentations of onychomycosis exist, including distal lateral subungual onychomycosis and dermatophytomas, each requiring different treatment approaches.
- Dermoscopic features, such as the Aurora borealis pattern, can aid in the diagnosis of onychomycosis and distinguish it from other nail disorders.
- Confirmatory testing is crucial to ensure accurate diagnosis before initiating treatment, due to the similarity of onychomycosis to other nail conditions.
- Current FDA-approved topical treatments for onychomycosis include ciclopirox, efinaconazole, and tavaborole, each with varying efficacy rates.
- Newer topical treatments, such as MOB-015, show promise but also highlight challenges like nail opacity affecting complete cure rates.
- Ongoing research is exploring new drug developments for onychomycosis, including ME111, amphotericin B, and NP213, which may enhance treatment options in the future.
- Albucker SJ, Falotico JM, Choo ZN, Matushansky JT, Lipner SR. J Fungi. 2023 Jun 29;9(7):712.
- Benedict K, Lipner SR, Lockhart SR, Gold JAW. JAAD Int. 2023 May 5;12:43-45.
- Lipner SR, Scher RK. J Am Acad Dermatol. 2019 Apr;80(4):835-851.
- Starace M et al. Mycoses. 2021 May;64(5):511-519.
- Lipner SR, Scher RK. Curr Med Res Opin. 2016 May;32(5):865-7.
- Lipner SR, Scher RK. JAMA Dermatol. 2016 Jul 1;152(7):847.
- Gupta AK et al. J Cutan Med Surg. 2018 Mar/Apr;22(2):129-141.
- Litaiem N, et al. Dermatol Pract Concept. 2023 Jan 1;13(1):e2023072
- Piraccini BM, et al. Dermatol Ther. 2012 Nov-Dec;25(6):594-602.
- Lipner SR, Scher RK. J Am Acad Dermatol. 2019 Apr;80(4):853-867.
- Gupta AK et al. J Am Acad Dermatol. 2021 Jul;85(1):95-104.
- Gregoriou S, et al. J Fungi (Basel). 2022 Oct 14;8(10):1079.
- Mercer DK et al. Med. Mycol. 2020;58:1064-1072.